Division of Cardiology, Faculty of Medicine & Dentistry, University of Alberta, Edmonton, Alberta, Canada


  • Reviews   
    Efficacy and safety of mineralocorticoid receptor antagonist therapy in heart failure with reduced ejection fraction
    Author(s): Arden R Barry*, Sheri L Koshman and Glen J Pearson

    oBjECTIVES: To summarize the efficacy and safety of mineralocorticoid receptor antagonists (MRAs) compared with placebo for the treatment of heart failure with reduced ejection fraction (HFrEF) by assessing clinically relevant end points of randomized controlled trials. METhoDS: The Medline, EMBASE, Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews, ACP Journal Club, DARE and International Pharmaceutical Abstracts databases were searched from inception to June 2014. Three authors independently reviewed and identified relevant articles. Included were randomized, doubleblinded, placebo-controlled trials that investigated spironolactone or eplerenone in adult patients with HFrEF regardless of etiology or symptomatology. RESulTS: The search strategy identified 726 articles; three met the inclusion criteria and included a total of 11,03.. Read More»
    DOI: 10.4172/2368-0512.1000012